Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2018 September;60(3) > Panminerva Medica 2018 September;60(3):109-16

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Panminerva Medica 2018 September;60(3):109-16

DOI: 10.23736/S0031-0808.18.03462-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Peroxisome proliferator-activated receptor gamma: promising target in glioblastoma

Gaurav GUPTA 1 , Gautam SINGHVI 2, Dinesh K. CHELLAPPAN 3, Sanjay SHARMA 4, Anurag MISHRA 5, Rajiv DAHIYA 6, Terezinha de JESUS ANDREOLI PINTO 7, Kamal DUA 8

1 School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, India; 2 Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India; 3 Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia; 4 NMIMS, School of Pharmacy & Technology Management, Shirpur, India; 5 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur, India; 6 Laboratory of Peptide Research and Development, School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago; 7 Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil; 8 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, Australia


PDF


Glioblastoma, also known as glioblastoma multiforme, is the most common and worldwide-spread cancer that begins within the brain. Glioblastomas represent 15% of brain tumors. The most common length of survival following diagnosis is 12 to 14 months with less than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically 3 months. Among all receptors, special attention has been focused on the role of peroxisome proliferator-activated receptors (PPARs) in glioblastoma. PPARs are ligand-activated intracellular transcription factors. The PPAR subfamily consists of three subtypes encoded by distinct genes named PPARα, PPARβ/δ, and PPARγ. PPARγ is the most extensively studied subtype of PPAR. There has been interesting preliminary evidence suggesting that diabetic patients receiving PPARγ agonists, a group of anti-diabetics, thiazolidinedione drugs, have an increased median survival for glioblastoma. In this paper, the recent progresses in understanding the potential mechanism of PPARγ in glioblastoma are summarized.


KEY WORDS: PPAR gamma - Glioblastoma - Neoplasms - STAT3 transcription factor - Receptors, Wnt - Transforming growth factor beta

top of page